» Articles » PMID: 22506010

Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk

Overview
Journal PLoS One
Date 2012 Apr 17
PMID 22506010
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The minor allele of rs11136000 within CLU is strongly associated with reduced Alzheimer's disease (AD) risk. The mechanism underlying this association is unclear. Here, we report that CLU1 and CLU2 are the two primary CLU isoforms in human brain; CLU1 and CLU2 share exons 2-9 but differ in exon 1 and proximal promoters. The expression of both CLU1 and CLU2 was increased in individuals with significant AD neuropathology. However, only CLU1 was associated with the rs11136000 genotype, with the minor "protective" rs11136000T allele being associated with increased CLU1 expression. Since CLU1 and CLU2 are predicted to encode intracellular and secreted proteins, respectively, we compared their expression; for both CLU1 and CLU2 transfected cells, clusterin is present in the secretory pathway, accumulates in the extracellular media, and is similar in size to clusterin in human brain. Overall, we interpret these results as indicating that the AD-protective minor rs11136000T allele is associated with increased CLU1 expression. Since CLU1 and CLU2 appear to produce similar proteins and are increased in AD, the AD-protection afforded by the rs11136000T allele may reflect increased soluble clusterin throughout life.

Citing Articles

Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimer's disease in humans.

Ramsden C, Cutler R, Li X, Keyes G bioRxiv. 2025; .

PMID: 39868210 PMC: 11761642. DOI: 10.1101/2025.01.17.633633.


Alzheimer's disease protective allele of modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication.

Zhao X, Li Y, Zhang S, Sudwarts A, Zhang H, Kozlova A medRxiv. 2024; .

PMID: 39185522 PMC: 11343251. DOI: 10.1101/2024.08.14.24312009.


Genetic biomarkers of cognitive impairment and dementia of potential interest in CKD patients.

Zoccali C, Capasso G J Nephrol. 2024; 37(9):2473-2479.

PMID: 38970746 DOI: 10.1007/s40620-024-02006-6.


The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj mice.

El-Darzi N, Mast N, Li Y, Dailey B, Kang M, Rhee D Cell Mol Life Sci. 2023; 80(7):194.

PMID: 37392222 PMC: 10314885. DOI: 10.1007/s00018-023-04848-y.


Clusterin/apolipoprotein J, its isoforms and Alzheimer's disease.

Milinkeviciute G, Green K Front Aging Neurosci. 2023; 15:1167886.

PMID: 37122381 PMC: 10133478. DOI: 10.3389/fnagi.2023.1167886.


References
1.
Bell R, Sagare A, Friedman A, Bedi G, Holtzman D, Deane R . Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2006; 27(5):909-18. PMC: 2853021. DOI: 10.1038/sj.jcbfm.9600419. View

2.
. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997; 18(4 Suppl):S1-2. View

3.
Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J . Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000; 50(4):305-15. DOI: 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L. View

4.
Falgarone G, Chiocchia G . Chapter 8: Clusterin: A multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res. 2009; 104:139-70. DOI: 10.1016/S0065-230X(09)04008-1. View

5.
Kimura K, Yamamoto M . Modification of the alternative splicing process of testosterone-repressed prostate message-2 (TRPM-2) gene by protein synthesis inhibitors and heat shock treatment. Biochim Biophys Acta. 1996; 1307(1):83-8. DOI: 10.1016/0167-4781(96)00017-6. View